Aiming for U.S. and European Approvals by 2028

Gentipharma announced on July 13 that it has signed a regulatory support agreement with Knoell Animal Health, a global animal pharmaceutical regulatory specialist, for the approval and development of Jedecure, its pet cognitive dysfunction (dementia) treatment, in the United States and Europe.


Under this agreement, Knoell will provide comprehensive support for regulatory and approval strategies targeting the Center for Veterinary Medicine (CVM) under the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). The main areas of support include: establishing global approval strategies; pre-meetings with the FDA and EMA; CMC development support; preparation of approval documents; responses to regulatory agencies; and review of accelerated approval strategies. The project will continue through December 2026.


Zhentipharma's treatment for cognitive dysfunction (dementia) in companion dogs, Jedacure. Zhentipharma

Zhentipharma's treatment for cognitive dysfunction (dementia) in companion dogs, Jedacure. Zhentipharma

View original image

Gentipharma is also accelerating efforts to strengthen its manufacturing base for global commercialization. In partnership with Chanelle Pharma, an animal pharmaceutical specialist in Ireland, the company is jointly advancing formulation development, establishment of production processes, quality management system enhancements, and CMC documentation in compliance with FDA and EMA standards. The two companies recently held an operations committee meeting to review key milestones such as the construction of manufacturing facilities and stability testing, aiming to complete U.S. and European approvals by 2028.


Jedecure is the world's first dual-target pet cognitive dysfunction treatment, approved for the first time in Korea in 2021. It is recognized as a first-in-class innovative drug that provides both symptom improvement and disease treatment efficacy. Currently, it is prescribed at approximately 2,300 veterinary hospitals in Korea, achieving sales growth of 30–40% annually and recording sales of about 1 billion won in the first half of this year.


Gentipharma plans to accelerate its entry into the global animal pharmaceutical market by expanding its business into major countries such as Japan and China, building on approvals in the United States and Europe.



Byungjoo Kwak, CEO of Gentipharma, stated, "This agreement with Knoell marks a major turning point for the global commercialization of Jedecure. Through collaboration with Knoell and Chanelle Pharma, we will successfully enter the U.S., European, and Asian markets and develop Jedecure as a world-leading treatment for dementia in companion animals."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing